Top Injectable Manufacturer in Guyana – Reliable Pharmaceutical Solutions
Last Updated: September 11, 2026
TL;DR: Guyana names the regulators it leans on — the United States, Canada, the United Kingdom and Australia — and India is not among them. But it leans harder than any other CARICOM state on the Caribbean Regulatory System, which accepts a WHO-prequalified finished product as an eligibility route. Guyana has registered 164 CRS-recommended products since October 2017, against Haiti's five. The door is open; it is simply not the door marked CDSCO.
Key Takeaways
Guyana's Food and Drug Department states it relies on assessments from the United States, Canada, the United Kingdom and Australia, falling back on WHO prequalification or a Caribbean Regulatory System recommendation. CDSCO appears on none of those lists.
The CRS accepts WHO-prequalified finished products directly, charges US$300 per application, and currently turns dossiers around in about 60 days. A recommendation registers nothing — it converts into a national authorisation, target 120 days, with an importer named.
Every one of the 210 pharmaceutical contracts in the national tender register was awarded by National Competitive Bidding. Bidder registration requires Guyanese tax, social-security and VAT identity, so a foreign manufacturer cannot bid alone.
Import licences are issued per consignment, the importer must be under a pharmacist's direct control with registered premises, and stock must arrive with at least 75% of shelf life remaining.
Introduction: What an Injectable Manufacturer in Guyana Has to Prove
Guyana answers this series' standing question more directly than most. Its Food and Drug Department has stated that it relies on full assessment of safety, efficacy and quality from listed reference authorities — the United States, Canada, the United Kingdom and Australia — and that where those are not met it relies on WHO prequalification or a recommendation reaching it through the Caribbean Regulatory System. India's CDSCO is on none of those lists.
What makes Guyana interesting is the second half of that sentence, which most supplier pages never quote. WHO prequalification is not a consolation route here; it is a named eligibility criterion. The Caribbean Regulatory System, run as a regulatory unit inside the Caribbean Public Health Agency, explicitly accepts applications for review of finished products prequalified by WHO, alongside products approved by a regional-reference or stringent authority. For an Indian manufacturer, that is the one gate whose key can be cut in Gujarat.
What Sets a World-Class Injectable Manufacturer in Guyana Apart
Guyana is not a marginal user of that system — it is the anchor customer. Of roughly 353 products the CRS has recommended since 2017, Guyana has registered 164, against five in Haiti and two in the Bahamas. The Acting Director of Guyana's Food and Drug Department has said on the record that the pathway runs in parallel with national registration and has provided an efficient alternative during periods of high workload, when meeting the 120-day processing timeline may be challenging.
The practical economics are modest and knowable. A CRS application costs US$300 for a manufacturer or marketing-authorisation holder, or US$150 where a local importer submits — the lower fee deliberately pushes manufacturers to file through importers. A decision is due within 90 calendar days of dossier acceptance, with a current turnaround reported at around 60, and a recommendation is valid for five years. But a recommendation registers nothing by itself: converting it into a lawful authorisation means a national application form, the CRS assessment report and certificate, the national fee, and a named importer — a target of 120 days.
Quality Systems Behind Every Sterile Injectable We Ship to Guyana
Guyana's door is opened by WHO prequalification or a stringent-authority approval, so the work sits in the plant. Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials, and stability follows ICH Q1A with Q1B photostability.
Two Guyanese requirements should be designed in rather than discovered late. Stock must arrive with at least 75% of its stated shelf life remaining, which argues for fresh manufacture against a confirmed order. And labelling must be in English — brand name, generic name, manufacturer address and the patient leaflet — with foreign-language labelling liable to seizure. Dossiers are assembled in CTD format, with ACTD available where a regulator prefers it; we found no published Guyanese dossier-format guideline and therefore assert none.
Working out whether the CRS route fits your product? Talk to our regulatory team
Why Farbe Firma is the Trusted Injectable Manufacturer in Guyana for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Guyana we can build the dossier and supply the WHO-format certificate of a pharmaceutical product and GMP certificate. What we cannot do is import or bid. The importer must be a Guyanese business under a pharmacist's direct control, with registered premises, holding a licence valid only for the particular importation it was issued for. We hold no Guyanese registration and recommend no distributor we have not verified.
Anyone pitching Guyana on tender volume should look at how those tenders are actually let. Across the whole published award register, all 210 pharmaceutical and medical-supply awards were made by National Competitive Bidding and none by international bidding, and bidder registration requires Guyanese tax, social-security and VAT identity. Injectables are not tendered under that name either — they sit inside lotted pharmaceutical supply tenders, visible only in the lot schedules. One route needs no local agent: the regional health body's pooled funds — but they rest quality assurance on WHO prequalification and on regulators they recognise.
Read Guyana's economics carefully, because the headline indicator lies. Current health expenditure was 2.47% of GDP in 2023 — down from 4.90% in 2019 — which reads like retrenchment and is the opposite. Per-capita health spending rose over the same period from about US$314 to about US$505; the ratio collapsed because oil took the denominator up more than sixfold. Population was about 836,000 in 2025, though the 2022 census counted 878,674 — about 7% above the estimate series every per-capita figure divides by. Two live items belong in any plan: Guyana is drafting new medicines legislation, so the 1971 framework is mid-replacement, and a Life Sciences Park with European backing explicitly contemplates domestic pharmaceutical and vaccine manufacturing. We print no registration fee, because none is published.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Does Guyana accept Indian regulatory approval for medicines?
Not as a recognised approval. Guyana's Food and Drug Department has stated it relies on assessment from the United States, Canada, the United Kingdom and Australia, with WHO prequalification or a Caribbean Regulatory System recommendation as the fallback. CDSCO appears on none of those lists, and its WHO maturity-level-3 and transitional listed-authority status is scoped to vaccines, not medicines. The workable route for an Indian manufacturer is WHO prequalification or an approval from a recognised authority.
Is the Indian Pharmacopoeia recognised in Guyana?
This needs care, because two things are true at once. The Indian Pharmacopoeia Commission signed a memorandum of understanding with Guyana's health ministry in November 2024 recognising the Indian Pharmacopoeia as a compendium of standards. But the drug standards schedule to Guyana's Food and Drugs Act lists eight pharmacopoeias and the Indian Pharmacopoeia is not among them, and we found no amendment adding it. Treat it as recognised by memorandum, not as settled in statute.
Does a Caribbean Regulatory System recommendation register my product in Guyana?
No, and CARPHA is explicit about it. A recommendation is an assessment outcome member states may rely on; when a state decides to register or import, its own process still applies. In practice that means a national application form, the CRS assessment report and certificate of recommendation, payment of the national fee, and identification of an importer, with a target of 120 calendar days.
Can an Indian manufacturer supply Guyana's public sector directly?
Not by bidding. Every pharmaceutical award in the published tender register was made by National Competitive Bidding, and bidder registration requires Guyanese tax, social-security and VAT registration, so a foreign manufacturer needs a locally registered partner. The one channel that does not require a local agent is regional pooled procurement — which applies its own quality gate, resting on WHO prequalification.
What does registration cost in Guyana, and how long does it take?
We can give one figure and not the other. The Food and Drug Department's published processing timeline is 120 days, and its Acting Director has acknowledged that meeting it can be challenging under workload. On fees we found no published schedule for national registration and will not invent one. The CRS fee is published and is US$300 per medicine application, or US$150 where a local importer submits.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments